SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Ligand (LGND) Breakout!
LGND 190.43-0.7%Feb 6 9:30 AM EST

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Henry Niman who wrote (447)1/7/1997 7:43:00 PM
From: Gary D Zehr   of 32384
 
Henry and all,

Latest news release from LGND

[ Yahoo | Write Us | Search | Headlines | Info ]

[ Business - Company - Industry - Finance - PR News - Business Wire - Quotes ]

Tuesday January 7 6:46 PM EST

Ligand Pharmaceuticals Inc to announce leptin
partnership

SAN FRANCISCO, Jan 7 (Reuter) - Ligand Pharmaceuticals Inc will later this month announce a
new partnership for research aimed at developing signals to trigger the natural production of leptin, a
protein shown to produce weight loss, President and Chief Executive Officer David Robinson said.

Robinson, who spoke at the Hambrecht and Quist Healthcare Conference here, said Ligand will
also pursue "several" corporate alliances in diabetes research in 1997. Some of its research will
focus on the effectiveness of its cancer drug candidate, Targretin, as a diabetes treatement.
Robinson said initial findings show a link in treating the two diseases.

Ligand will increasingly focus on upfront fees and profit sharing arrangements in the new corporate
partnerships it enters, Robinson said.

He said the $85 million in cash the company currently has on hand is sufficient to carry the company
into 1997, when it expects commercialization of lead product candidates to begin.

The company's Phase III trials of the Panretin topical agent for Kaposi's sarcoma are expected to
be completed in early 1997. In addition, Robinson said the progress in Phase III trials of its
Targretin cancer drug has been "exciting, suggesting expanded applications for treating cancer."

Robinson said he expects the company's sales in 1997 to grow at about the same rate as 1996,
when they rose to an estimated $32.8 million, from $24.5 million the year before. Revenues, he
said, should cover about half of the company's cash burn.

Help

Back to Ligand Pharmaceuticals Inc news page

Copyright c 1996 Reuters Limited. All rights reserved. Republication or redissemination of the contents of this
screen are expressly prohibited without the written consent of Reuters Limited
Questions or Comments?
Any comments Gary
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext